AATD Diagnosis and Alpha-1 Testing
Practical orientation for clinicians and informed patients
By Mark Egly Foundation
This page summarizes established approaches to diagnosing Alpha-1 Antitrypsin Deficiency (AATD) and when testing is often considered. It is educational. It is not a clinical guideline and does not replace specialty society recommendations or your clinical judgment.
For Mark Egly research hypotheses about conditions beyond classic lung and liver disease, see the disease catalog and hub pages. Those claims are labeled as hypotheses separately.
Why testing matters
AATD is underdiagnosed. People with early emphysema, unexplained COPD (including in never smokers), unexplained liver disease, or a family history of AATD may benefit from evaluation. Identifying AATD can change monitoring, counseling, and eligibility discussions for augmentation therapy in appropriate lung disease settings.
Who often warrants testing
Common clinical triggers include:
- COPD or emphysema with early onset or limited smoking history
- Unexplained chronic liver disease or neonatal liver disease
- Family history of AATD
- Panniculitis or certain rare AATD related presentations
- Interest in cascade testing of first degree relatives after a confirmed index case
Broader research questions about autoimmune, cancer, or neurological associations are investigational. See AATD and autoimmune diseases, AATD and cancer prevention, and AATD and neurological conditions.
Testing pathway (high level)
- Serum AAT level. A low circulating level prompts further workup. Interpret in clinical context (acute phase response can raise levels).
- Phenotyping or genotyping. Confirms protein variants or SERPINA1 genotype (for example PIZZ, PIMZ, and other alleles).
- Clinical correlation. Integrate lung imaging and function, liver evaluation, family history, and specialist referral as needed.
Laboratory menus and reference ranges vary. Follow your institution's protocols and current specialty guidance.
Genetic testing for COPD
When COPD or emphysema seems disproportionate to exposure history, AATD testing is a high value step. Framing the conversation as "genetic testing for COPD risk" helps patients understand why a blood test or genotype assay is being ordered.
Patients can also review symptoms and medications and treatments in plain language.
Clinical guidelines and resources
Point clinicians and patients to authoritative sources for current standards:
- Alpha-1 Foundation clinical resources
- American Thoracic Society / European Respiratory Society statements on AATD (as applicable to your practice)
- NIH Genetics Home Reference / MedlinePlus consumer summaries for patient education
The Mark Egly Foundation does not replace those bodies. We focus on awareness, research funding, and physician networking through Uniting Doctors.
Uniting Doctors
If you practice in pulmonology, hepatology, primary care, or another specialty that sees AATD related presentations, learn about our physician network:
Patient facing tools
- Self-check (non diagnostic education)
- Newly diagnosed resources
- Ask the MD
Support diagnosis awareness
Help fund education and research through ways to give.